Provided by Tiger Trade Technology Pte. Ltd.

Taysha Gene Therapies, Inc.

5.16
-0.1800-3.37%
Post-market: 5.160.00000.00%19:30 EDT
Volume:2.40M
Turnover:12.32M
Market Cap:1.68B
PE:-12.51
High:5.24
Open:5.24
Low:5.01
Close:5.34
52wk High:7.30
52wk Low:2.71
Shares:325.83M
Float Shares:233.00M
Volume Ratio:1.20
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4126
EPS(LYR):-0.3409
ROE:-47.05%
ROA:-23.82%
PB:4.34
PE(LYR):-15.14

Loading ...

Taysha Gene Therapies to Present Reveal Phase 1/2 Data for Rett Gene Therapy Tsha-102 at 2026 IRSF Meeting

Reuters
·
Jun 26

Taysha Gene Therapies management to meet with Piper Sandler

TIPRANKS
·
Jun 26

Taysha Gene Therapies Down over 11%, on Pace for Largest Percent Decrease Since May 2025

Dow Jones
·
Jun 26

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

MT Newswires Live
·
Jun 25

Taysha Gene Therapies 32.5M share Spot Secondary priced at $6.00

TIPRANKS
·
Jun 25

Taysha Gene Therapies - Prices Offering of 32.5 Mln Shares at $6 Each

THOMSON REUTERS
·
Jun 25

Taysha Gene Therapies Inc: Files for Mixed Shelf Offering of up to $200 Mln - SEC Filing

THOMSON REUTERS
·
Jun 25

Taysha Gene Therapies announces $200M common stock offering

TIPRANKS
·
Jun 25

Taysha Gene Therapies Launches USD 200 Million Common Stock, Pre-funded Warrants Offering

Reuters
·
Jun 25

Taysha Gene Therapies Inc: Commenced an Underwritten Public Offering of $200.0 Mln Shares of Its Common Stock and Pre-funded Warrants

THOMSON REUTERS
·
Jun 25

Jefferies Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)

TIPRANKS
·
Jun 23

Taysha Gene Therapies price target raised to $11 from $8 at Citizens

TIPRANKS
·
Jun 23

Taysha Gene Therapies Is Maintained at Buy by Needham

Dow Jones
·
Jun 23

Taysha Completes REVEAL Dosing, Advances Rett Gene Therapy

TIPRANKS
·
Jun 22

Taysha completes dosing in REVEAL pivotal trial of TSHA-102 for Rett syndrome

Reuters
·
Jun 22

Taysha Gene Therapies - Topline Data and FDA Feedback Expected in First Half of 2027

THOMSON REUTERS
·
Jun 22

Taysha Gene Therapies - Tsha-102 Shows No Treatment-Related Saes or Dlts as of June 2026

THOMSON REUTERS
·
Jun 22

Taysha Gene Therapies - Bla-Enabling Ppq Campaign for Tsha-102 Expected to Complete in Q4 2026

THOMSON REUTERS
·
Jun 22

Taysha Gene Therapies Announces Completion of Dosing in Reveal Pivotal Trial and Reports Longer-Term Clinical Data From Part a of Reveal Phase 1/2 Trials Evaluating Tsha-102 for Rett Syndrome

THOMSON REUTERS
·
Jun 22

Taysha Gene Therapies - 100% of Reveal Part a Patients Gained or Regained Developmental Milestone by 12 Months

THOMSON REUTERS
·
Jun 22